Pathogenesis and treatment of encapsulating peritoneal sclerosis: Basic and translational research

Peritoneal Dialysis International

Volumn 28, Issue SUPPL. 5, 2008, Pages

  Schmidt, Darren W ^a   Flessner, Michael F ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokine; Foreign body; Inflammation; Peritoneum

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOGENESIS INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; BETA 2 MICROGLOBULIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN DEGRADATION PRODUCT; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GELATINASE B; HEAT SHOCK PROTEIN 47; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; MYCOPHENOLIC ACID; PLATELET DERIVED GROWTH FACTOR; PREDNISOLONE; PREDNISONE; SCATTER FACTOR; TAMOXIFEN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; TRYPTASE; VASCULOTROPIN;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DISEASE MARKER; EARLY DIAGNOSIS; ENCAPSULATING PERITONEAL SCLEROSIS; GENE THERAPY; HEMODIALYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INTESTINE OBSTRUCTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PERITONEAL DISEASE; PERITONEUM ADHESION; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; CHRONIC KIDNEY FAILURE; PATHOLOGY; PERITONEUM; REVIEW; SCLEROSIS;

ANIMALS; HUMANS; KIDNEY FAILURE, CHRONIC; PERITONEAL DIALYSIS; PERITONEUM; SCLEROSIS;

EID: 65849405864     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080802805s03     Document Type: Article

References (56)

1. Kawaguchi Y, Kawanishi H, Mujais S, Topley N, Oreopoulos D. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in PeritoneaL Dialysis. Perit Dial Int 2000; 20(Suppl 4):S43-55.
2. Gandhi V, Humayun H, Ing L Daugirdas J, JabLokow V, Iwatsuki S, et al. Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients. Arch Intern Med 1980; 140:1201-3.
3. Duman S, Ozbek S, Gunay E, Bozkurt D, Asci G, Sipahi S, et al. What does peritoneal thickness in peritoneal dialysis patients tell us? Adv Perit Dial 2007; 23:28-33.
4. Nakamoto H. Encapsulating peritoneal sclerosis - a clinician's approach to diagnosis and medical treatment. Perit Dial Int 2005; 25(Suppl 4):530-8.
5. Kawaguchi Y, Saito A, Kawanishi H, Nakayama M, Miyazaki M, Nakamoto H, et al. Recommendations on the management of encapsulating peritonea L sclerosis in Japan, 2005: diagnosis, predictive markers, treatment, and preventive measures. Perit Dial Int 2005; 25(Suppt 4):S83-95.
6. Nakamoto H, Kawaguchi Y, Suzuki H. Encapsulating peritoneal sclerosis in patients undergoing continuous ambulatory peritoneal dialysis in Japan. Adv Perit Dial 2002; 18:119-23.
7. Yamamoto R, Otsuka Y, Nakayama M, Maruyama Y, Katoh N, Ikeda M, et al. Risk factors for encapsulating peritoneal sclerosis in patients who have experienced peritoneal dialysis treatment. Clin Exp Nephrol 2005; 9:148-52.
8. Summers A, Clancy M, Syed F, Harwood N, Brenchley P, Augustine T, et al. Single-center experience of encapsulating peritoneat sclerosis in patients on peritoneal dialysis for end-stage renal failure. Kidney Int 2005; 68: 2381-8.
9. Kawanishi H, Kawaguchi Y, Fukui H, Hara S, Imada A, Kubo H, et al. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am 3 Kidney Dis 2004; 44:729-37.
10. Otsuka Y, Nakayama M, Ikeda M, Sherif AM, Yokoyama K, Yamamoto H, et al. Restoration of peritoneal integrity after withdrawal of peritoneal dialysis: characteristic features of the patients at risk of encapsulating peritoneal sclerosis. Clin Exp Nephrol 2005; 9:315-19.
11. Korte MR, Yo M, Betjes MGH, Fieren MW, van Saase JC, Boer WH, et al. Increasing incidence of severe encapsulating peritoneal sclerosis after kidney transplantation. Nephrol Dial Transplant 2007; 22:2412-14.
12. Fieren MWJA, Betjes MGH, Korte MR, Boer WH. Post-transplant encapsulating peritoneal sclerosis: a worrying new trend? Perit Dial Int 2007; 27:619-24.
13. Dejagere T, Evenepoel P, Claes K, Kuypers D, Maes B, Vanrenterghem Y. Acute-onset, steroid-sensitive, encapsulating peritoneal sclerosis in a renal transplant recipient. Am J Kidney Dis 2005; 45:E33-7.
14. Moriishi M, Kawanishi H, Tsuchiya S. Impact on peritoneal membrane of use of icodextrin-based dialysis solution in peritonea dialysis patients. Adv Perit Dial 2006; 22:24-8.
15. Breborowicz A, Oreopoutos D. Is normal saline harmfulto the peritoneum? Perit Dial Int 2005; 25(Suppl4):S67-70.
16. Hoff C. Experimental animal models of encapsulating peritoneal sclerosis. Perit Dial Int 2005; 25(Suppt 4): S57-66.
17. Junor B, Briggs D, Forwell M, Dobbie J, Henderson I. Sclerosing peritonitis-the contribution of chlorhexidine in alcohol. Perit Dial Bull 1985; 5:101-4.
18. Mackow R, Winchester J, Argy W, Andrews P, Fields P, Bates, S, et al. Sclerosing encapsulating peritonitis in rats: an experimental study with intraperitoneal antiseptics. Contrib Nephrol 1987; 57:213-18.
19. Mackow R, Argy W, Winchester J, Rakowski T, Fields P, Rotellar C, et al. Sclerosing encapsulating peritonitis in rats induced by long-term intraperitoneal administration of antiseptics. Lab Clin Med 1988; 112:363-71.
20. Sawada T, Ishii Y, Tojimbara T, Nakajima I, Fuchinoue S, Teraoka S. The ACE inhibitor, quinapril, ameliorates peritoneal fibrosis in an encapsulating peritoneal sclerosis model in mice. Pharmacol Res 2002; 46:505-10.
21. Nakamoto H, Imai H, Ishida Y, Yamanouchi Y, Inoue T, Okada H, et al. New animal models for encapsulating peritoneal sclerosis - role of acidic solution. Perit Dial Int 2001; 21(Suppl 3):S349-53.
22. Levine S, Saltzman A. Abdominal cocoon: an animal model for a complication of peritoneal dialysis. Perit Dial Int 1996; 16:613-16.
23. Okada H, Inoue T, Kanno Y, Kobayashi T, Watanabe Y, Ban S, et al. Selective depletion of fibroblasts preserves morphotogy and the functional integrity of peritoneum in transgenic mice with peritoneal fibrosing syndrome. Kidney Int 2003; 64:1722-32.
24. Nishino T, Miyazaki M, Abe K, Furusu A, Mishima Y, Harada T, et al. Antisense oligonucleotides against collagen-binding stress protein HSP47 suppress peritoneal fibrosis in rats. Kidney Int 2003; 64:887-96.
25. Hirahara I, Inoue M, Okuda K, Ando Y, Muto S, Kusano E. The potential of matrix meta Roproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis - a multicentre study in Japan. Nephrol Dial Transplant 2007; 22:560-7.
26. Hirahara I, Umeyama K, Urakami K, Kusano E, Masunaga Y, Asano Y. Serial analysis of matrix metalloproteinase-2 in dialysate of rat sclerosing peritonitis models. Clin Exp Nephrol 2001; 5:103-8.
27. Ro Y, Hamada C, Inaba M, Hayashi K, Sho I, Fukui M. Effects of matrix metalloproteinase inhibitor ONO-4817 on morphological changes in chtorhexidine gtuconate-induced peritoneal sclerosis in rats [Abstract]. J Am Soc Nephrol 2003; 14:593A.
28. Matsuoka T, Maeda X Matsuo K, Naiki Y, Tamai Y, Sakaguchi M, et al. Hepatocyte growth factor prevents peritoneal fibrosis in an animal model of encapsulating peritoneal sclerosis. J Nephrol 2008; 21:64-73.
29. Yanez-Mo M, Lara-Pezzi E, Selgas R, Ramirez-Huesca M, Dominguez-Jimenez C, Jimenez-Heffernan JA, et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 2003; 348:403-13.
30. Margetts P, Kolb M, Galt T, Hoff C, Shockley T, Gauldi J. Gene transfer of transforming growth factor-beta 1 to the rat peritoneum: effects on membrane function. J Am Soc Nephrol 2001; 12:2029-39.
31. Oh K, Margetts P. Cytokines and growth factors involved in peritoneal fibrosis of peritoneal dialysis patients. Int J Artif Organs 2005; 28:129-34.
32. Del Peso G, Jimenez-Heffernan J, Bajo M, Hevia C, Aguilera A, Castro M, et al. Myofibroblastic differentiation in simple peritoneal sclerosis. Int J Artif Organs 2005; 28:135-40.
33. Alscher DM, Braun N, Biegger D, Fritz P. Peritoneal mast cells in peritoneal dialysis patients, particularly in encapsulating peritoneal sclerosis patients. Am J Kidney Dis 2007; 49:452-61.
34. Sherif AM, Yoshida H, Maruyama Y, Yamamoto H, Yokoyama K, Hosoya T, et al. Comparison between the pathology of encapsulating sclerosis and simple sclerosis of the peritoneal membrane in chronic peritoneal dialysis. Ther Apher Dial 2008; 12:33-41.
35. Garosi G, Di Paolo N, Sacchi G, Gaggiotti E. Sclerosing peritonitis: a nosological entity. Perit Dial Int 2005; 25(Suppl 3):S110-12.
36. Di Paolo N, Sacchi G, Garosi G, Taganelli P, Gaggiotti E. Simple peritoneal sclerosis and sclerosing peritonitis: related or distinct entities? Int J Artif Organs 2005; 28: 117-28.
37. Kawaguchi Y, Tranaeus A. A historical review of encapsulating peritoneal sclerosis. Perit Dial Int 2005; 25(Suppl 4):S7-13.
38. Kawanishi H. The pathogenesis and therapeutic option of encapsulating peritoneal sclerosis. Int J Artif Organs 2005; 28:150-5.
39. Kawanishi H, Moriishi M, Tsuchiya S. Experience of 100 surgical cases of encapsulating peritoneal sclerosis: investigation of recurrent cases after surgery. Adv Perit Dial 2006; 22:60-4.
40. Kawanishi H, Watanabe H, Moriishi M, Tsuchiya S. Successful surgical management of encapsulating peritoneal sclerosis. Perit Dial Int 2005; 25(Suppl 4):S39-47.
41. Wong C. Clinical experience with tamoxifen in encapsulating peritoneal sclerosis. Perit Dial Int 2006; 26:183-4.
42. Wong C, Beshir S, Khalil A, Pai P, Ahmad R. Successful treatment of encapsulating peritoneal sclerosis with azathioprine and prednisolone. Perit Dial Int 2005; 25:285-7.
43. Lafrance J-P, Létourneau I, Ouimet D, Bonnardeaux A, Leblanc M, Nicole Mathieu, et al. Successful treatment of encapsulating peritoneal sclerosis with immunosuppressive therapy. Am J Kidney Dis 2008; 51:e7-10.
44. Eltoum M, Wright S, Atchley J, Mason J. Four consecutive cases of peritoneal dialysis-related encapsulating peritoneal sclerosis treated successfully with tamoxifen. Perit Dial Int 2006; 26:203-6.
45. Moustafellos P, Hadjianastassiou V, Roy D, Velzeboer N, Maniakyn N, Vaidya A, et al. Tamoxifen therapy in encapsulating sclerosing peritonitis in patients after kidney transplantation. Transplant Proc 2006; 38:2913-14.
46. Duman S, Sen S, Duman C, Oreopoulos D. Effect of valsartan versus lisinopril on peritoneal sclerosis in rats. Int J Artif Organs 2005; 28:156-63.
47. Abe K, Miyazaki M, Yoshio Y, Nishino T, Furusu A, Harada T. Angiotensin II blockade ameliorates peritoneal fibrosis caused by chlorhexidine gluconate [Abstract]. J Am Soc Nephrol 2002; 13:309A.
48. Imai H, Nakamoto H, Fukushima R, Ishida Y, Yamanouchi Y, Suzuki H. Role of adhesion molecules in the progression of peritoneal sclerosis. Adv Perit Dial 2003; 19:180-5.
49. Io H, Hamada C, Ro Y, Ito Y, Hirahara I, Tomino Y. Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int 2004; 65:1927-36.
50. Duman S, Sen S, Sozmen E, Oreopoulos D. Atorvastatin improves peritoneal sclerosis induced by hypertonic PD solution in rats. Int J Artif Organs 2005; 28:170-6.
51. Izumotania T, Ishimurab E, Yamamotoa T, Otoshia T, Okunoa S, Inabab M, et al. Correlation between peritoneal mesothelial cell cytology and peritoneal histopathology with respect to prognosis in patients on continuous ambulatory peritoneal dialysis. Nephron 2001; 89:43-9.
52. Uchiyama-Tanaka Y, Mori Y, Kosaki A, Kimura T, Moriishi M, Kawanishi H, et al. Plasma S100A12 concentrations in peritoneal dialysis patients and subclinical chronic inflammatory disease. Ther Apher Dial 2008; 12:28-32.
53. Yokoyama K, Yoshida H, Matsuo N, Maruyama Y, Kawamura Y, Yamamoto R, et al. Serum beta2 microglobulin (beta2MG) level is a potential predictor for encapsulating peritoneal sclerosis (EPS) in peritoneal dialysis patients. Clin Nephrol 2008; 69:121-6.
54. Masunaga Y, Hirahara I, Shimano Y, Kurosu M, Iimura O, Miyata Y, et al. A case of encapsulating peritoneal sclerosis at the clinical early stage with high concentration of matrix metalloproteinase-2 in peritoneal effluent. Clin Exp Nephrol 2005; 9:85-9.
55. Kawanishi H, Fujimori A, Tsuchida K, Takemoto Y, Tomo T, Minakuchi J, et al. Markers in peritoneal effluent for withdrawal from peritoneal dialysis: multicenter prospective study in Japan. Adv Perit Dial 2005; 21:134-8.
56. Summers A, Brenchley P. An international encapsulating peritoneal sclerosis registry and DNA bank: why we need one now. Perit Dial Int 2006; 26:559-63.